Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of Filibuvir Plus Pegylated Interferon Alfa-2a And Ribavirin In Treatment-Naive, HCV Genotype 1 Infected Subjects
Brief Summary: The primary objective for this study is to determine if the addition of filibuvir to a standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the proportion of subjects who achieve a sustained viral response (SVR) compared to peginterferon/ribavirin (pegIFN/RBV) therapy alone.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: 12 Week Cohort; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: 16 Week Cohort; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort | Intervention Type: DRUG; Name: Pegylated interferon alfa-2a; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort, Control | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort, Control
B: Arm Label: Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (B); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (C); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Placebo, Peginterferon alpha-2a, ribavirin (D); Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a, Drug: ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (C) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: Peginterferon alpha-2a; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D)
C: Arm Label: 20mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 48mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 120mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 240mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 240mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 120mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 48mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 20mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm C

Answer: D